Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE: Effect of mepolizumab on clinical remission in severe asthma (Japan cohort)
jRCT1031230710Recruiting
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of mepolizumab in asthma and severe asthma, sponsored by GSK. Primary endpoint: Clinical remission at 12 months. Started May 2024; status: recruiting.
02
Drugs
mepolizumab
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on jRCT1031230710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230710.